Successful control of the first carbapenem-resistant *Klebsiella pneumoniae* outbreak in a Chinese hospital 2017–2019

Jiaying Zhu, Qi Li, Xiaoxia Li, Jianbang Kang, Yan Song, Junli Song, Donghong Yin and Jinju Duan

**Abstract**

**Background:** Carbapenem-resistant *Klebsiella pneumoniae* (CRKP) is considered as a serious global threat. CRKPs occurred only sporadically in the Second Hospital of Shanxi Medical University. Our study aimed to investigate and control the first outbreak of CRKP in our hospital occurred between October 2017 and August 2019.

**Methods:** The antimicrobial stewardship (AMS) workers have been implemented control measures properly. Clinical and epidemiological data were retrospectively collected from medical records. Carbapenemase genes were detected by modified carbapenem inactivation method (mCIM) test and the EDTA-modified carbapenem inactivation method (eCIM) test. Resistance genes were identified by polymerase chain reaction (PCR) and sequencing. Genetic relatedness was studied by multilocus sequence typing (MLST).

**Results:** During the outbreak, 31 patients were infected with CRKP isolates. 20 (64.5%) patients were infected with KPC-2 and/or NDM-1 producing *K. pneumoniae*. Mostly MLST-sequence types belonged to ST11 (21/31). The outbreak was two major *K. pneumoniae* clusters present in epidemiologically linked patients.

**Conclusions:** Setting up AMS workers is potentially a highly efficient strategy for the successful control of the outbreak. A multimodal and multidisciplinary infection control strategy proved to be crucial. The emergence of CRKP in our hospital emphasizes the importance of continuous monitoring of these isolates, which helps to limit the spread of CRKPs and improve the level of management.

**Keywords:** Carbapenem-resistant *Klebsiella pneumoniae*, Infection control, NDM, KPC, Phenotypic detection, Transmission

**Introduction**

*K. pneumoniae* is one of the leading causes of hospital-acquired infections globally. Carbapenemases are widely used for the treatment of serious infections caused by multidrug resistant (MDR) *Enterobacteriaceae* such as AmpC β-lactamases and extended spectrum β-lactamases (ESBLs) [1]. However, in recent years, widespread use of carbapenemases have accelerated the growth of resistant strains in different regions [2]. The problem of antimicrobial resistance is highlighted by a recent increase of carbapenem-resistant *K. pneumoniae* (CRKP), which has largely been driven by the emergence and spread of mobile genetic elements carrying carbapenem resistance genes including either class B metallo-betalactamases (IMP, VIM, NDM) or classes A (KPC) and D (OXA-48) serine carbapenemases [3, 4]. KPC-producing strains, first reported in 1996 [5], are considered as one of the most common carbapenemases globally [3]. In China, KPC-producing *K. pneumoniae* strains have been identified since 2004 in Zhejiang Province [6] and have become endemic in many hospitals, with most of them harbouring...
blaKPC-2 allele [7]. In addition, blaNDM-1 is now considered to be endemic in the Indian subcontinent [8] and reports of NDM-1-producing Klebsiella from hospital- and community-acquired infections elsewhere indicate global dispersion [9].

A total of 44 hospitals were included in the China Antimicrobial Surveillance Network (CHINET, www.chinets.com) in 2018. Most of the hospitals included are the largest tertiary-care teaching hospitals in each province or city which represent 26 provinces or cities. These provinces or cities have a population of about nine hundred million. It has reported that Carbapenem resistance among K. pneumoniae, especially cultured from cerebrospinal fluid, increased significantly from 18.6 to 64.1% in 2018 [10]. From 2005 to 2018, the resistance rates of K. pneumoniae to imipenem and meropenem were increased from 3.0 to 25%, 2.9 to 26.3%, respectively [10]. Dissemination of the CRKP strains is facilitated by inadequate infection prevention and control practice in healthcare settings, uncontrolled or poorly controlled antimicrobial use, sewage water treatment and general sanitation. The spread of such strains is associated with high mortality rates, limited treatment options and rapid dissemination of successful bacterial clones in the hospital setting. The occurrence of the above conditions can be effectively reduced by taking strict infection control measures [11]. In this report, we describe what we believe to be the first outbreak of CRKP in our hospital, which occurred from October 2017 to August 2019. Our aims were to assess the antimicrobial resistance phenotypes, the epidemiology, clinical features, outcomes and the challenges faced in controlling CRKP during the 23 months from October 2017 to August 2019 in a tertiary-care teaching hospital in Shanxi, China.

Materials and methods

Data collection

The Second Hospital of Shanxi Medical University is a 2076-bed tertiary-care teaching hospital. A total of 31 non-duplicated CRKP strains were isolated and identified from October 2017 to August 2019. All clinical and epidemiological data were retrospectively reviewed. All isolates in this study were defined as resistant to one of meropenem, imipenem or ertapenem. A CRKP-positive case was defined as any patient infected or colonized with CRKP. All isolates were identified by VITEK-2 Compact system (BioMerieux Italia S.p.A) and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (Bruker Daltonik, Bremen, Germany).

Antimicrobial susceptibility testing

Antimicrobial susceptibility was evaluated by the agar dilution and microdilution methods at the Second Hospital of Shanxi Medical University according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [12], and the results were interpreted according to CLSI categories and minimum inhibitory concentration (MIC) breakpoints. The breakpoint of tigecycline for K. pneumoniae was based on the US Food and Drug Administration standard. Escherichia coli ATCC 25922 were used as quality control standards for antimicrobial susceptibility testing.

Investigation of resistance mechanisms

To use the combined application of modified carbapenem inactivation method (mCIM) test and the EDTA-modified carbapenem inactivation method (eCIM) test for discriminating between serine- and metal-dependent (such as metallo-β-lactamases (MBLs) carbapenemases) [12, 13]. For 31 CRKP strains, polymerase chain reaction (PCR) was used to detect genes encoding carbapenemases (blaKPC, blaNDM, blaGES, blaIMP, blaVIM, blaGIM, and blaOXA-48), ESBLs, and AmpC β-lactamases (blaCTX-M-1,3,10,11,12,15, blaCTX-M-2,4,7,Toho-1, Toho-2, blaACT, blaOXA-23, blaCMY), as previously described [5, 14-18]. The colistin resistance gene mcr-1 was also detected by PCR, as previously described [19]. PCR products were purified with a QIAquick PCR Purification Kit (Qiagen, Valencia, CA, USA) and sequenced by Sanger sequencing on an ABI PRISM 3730XL system (Applied Biosystems, Foster City, CA, USA).

Multilocus sequence typing (MLST)

Multilocus sequence typing (MLST) was performed by amplifying the internal fragments of seven K. pneumoniae housekeeping genes according to the MLST website (https://bigsdb.pasteur.fr/). A phylogeny was showed by using the seven concatenated MLST gene sequences of all 31 strains. We constructed a refined maximum likelihood phylogeny by MEGA7 to study these isolates in greater detail.

Infection control program

In order to control the outbreak of infection, we have set up a working group on the antimicrobial stewardship (AMS) in August 2018. The AMS workers consisted of hospital administrators, health directors, physicians, nurses, clinical pharmacists, a microbiologist, an environmental cleaning staff and staffs from the infection management department, infectious diseases department and computer center department.

During the outbreak, strict infection control procedures were put in place including a) Rapid communication between microbiological laboratories and AMS workers was established to ensure early warning and timely sharing of any pertinent epidemiological information, access to online results of microbiological testing was already routinely available; b) Infection control specialists and clinical pharmacists put forward suggestions on rational drugs use in time and staffs underwent training courses. All CRKP
carriers were isolated in a single room with strict contact precautions and flagged in the hospital information system (HIS); c) The AMS workers enhanced chlorhexidine disinfection of the patients' room at least three times a day and implemented surveillance cultures of the hand and environment. The AMS team held meetings regularly for update the outbreak situation, the implemented measures and proposed future actions; d) All contact patients were systematically subjected to rectal and pharyngeal screening once a week; e) After CRKP-positive cases were discharged, the surroundings were cleaned in depth using a 500-ppm chlorine solution. High-touch surfaces such as door handles, bedside lockers and chairs and bed rails were emphasized by the hospital hygiene nurse manager for cleaning to reduce cross-transmission. Infection control staffs followed up the measures; f) When the affected patients transfer to other hospitals, these hospitals should be forewarned.

Results

Epidemiological investigation of the outbreak

Until 2018, CRKPs occurred only sporadically. During October 2017, CRKP was detected from one patient in Hematology ward, who was hospitalized because of PH-positive acute lymphoblastic leukemia with lack of granulocytes. The patient did test positive for CRKP from fecal culture which was turn out to be colonization. Two month later, the patient gradually tests positive from both sputum and blood again. That patient was defined as patient 01 (Fig. 1). After that in January 2018 the two index patients in the intensive care unit (ICU) were detected, whom defined as patient 02 and 03, neither had a history of hospitalization nor travel in a foreign country. Then three other patients were test positive for CRKP in 2 days and all of them were in the ICU, with no signs of infection or colonization on admission. They were in individual beds in the same room but had overlapping nurses, physicians, and respiratory technicians, they also shared thermometers (disinfection of alcohol cotton swabs) and stethoscopes before isolation precautions were ordered. At the affected wards new CRKP strains were isolated, five in January and three in February (Table 1). Some of them were in direct contact with patient 02 or 03 in the ICU, while others who came into contact with ICU of patient 02 or 03 were subsequently transferred to regular wards (Fig. 2). Some of the patients transferred to the regular wards were in the same room. In a few new CRKP-positive cases there was no direct contact with infected patients, however, they were in adjacent rooms and were cared for by the same doctor, nurse or environmental cleaning staff (Fig. 2).

From the October 2017 to August 2018, a total of 26 patients with KPC-2 and/or NDM-1 CRKP were found in ten different wards (including ICU), all with an epidemiological connection to the outbreak. As this was
| ID | Sex | Age(y) | APACHE II | Department when infection | Clinic samples | Outcome | CIM | eCIM | MLST | Carbapenemase KPC | NDM | Other | ESBL | AmpC | mcr-1 |
|----|-----|--------|-----------|---------------------------|----------------|---------|-----|-----|------|-----------------|-----|-------|------|------|------|
| P01 | F | 56 | 14 | Hematology | Blood | Death | 1 | - | ST147 | - | - | + | - | - |
| P02 | M | 62 | 32 | ICU | Respiratory secretions | Discharge | + | + | ST1 | - | NDM-1 | - | - | - |
| P03 | F | 78 | 12 | ICU | Respiratory secretions | Death | + | + | ST11 | KPC-2 | NDM-1 | - | - | - |
| P04 | M | 88 | 20 | ICU | Respiratory secretions | Death | + | + | ST11 | - | - | - | - | - |
| P05 | M | 52 | 26 | Respiratory | Respiratory secretions | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P06 | M | 48 | 20 | ICU | Respiratory secretions | Death | + | + | ST11 | - | - | - | - | - |
| P07 | M | 40 | 26 | ICU | Respiratory secretions | Death | + | + | ST11 | - | NDM-1 | - | - | - |
| P08 | M | 54 | 20 | Respiratory | Respiratory secretions | Death | + | + | ST11 | - | NDM-1 | - | - | - |
| P09 | M | 54 | 26 | ICU | Respiratory secretions | Death | + | + | ST11 | - | - | - | - | - |
| P10 | F | 85 | 14 | Gastroenterology | Secretions | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P11 | M | 56 | 25 | ICU | Respiratory secretions | Discharge | + | - | ST11 | KPC-2 | - | + | + | - |
| P12 | M | 76 | 24 | Neurosurgery | Cerebrospinal fluid | Death | + | + | ST11 | - | NDM-1 | - | - | - |
| P13 | M | 44 | 5 | General Surgery | Pus | Discharge | + | + | ST11 | - | - | - | - | - |
| P14 | M | 30 | 6 | Hematology | Respiratory secretions | Death | - | - | ST15 | - | - | - | - | - |
| P15 | M | 90 | 15 | Cardiothoracic Surgery | Blood | Discharge | + | + | ST11 | - | - | - | - | - |
| P16 | M | 62 | 10 | Hematology | Respiratory secretions | Discharge | + | + | ST3744 | - | NDM-1 | - | - | - |
| P17 | M | 66 | 13 | Nephrology | Respiratory secretions | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P18 | M | 62 | 8 | Rheumatology | Blood | Discharge | + | + | ST11 | - | - | - | - | - |
| P19 | F | 71 | 7 | Respiratory | Respiratory secretions | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P20 | M | 42 | 7 | ICU | Blood | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P21 | M | 57 | 9 | Hematology | Respiratory secretions | Discharge | + | + | * | - | NDM-1 | - | + | - |
| P22 | M | 70 | 29 | Neurosurgery | Respiratory secretions | Death | + | - | ST11 | KPC-2 | - | + | - | - |
| P23 | F | 44 | 18 | Hematology | Blood | Discharge | + | + | ST690 | - | NDM-1 | - | - | - |
| P24 | F | 76 | 11 | Neurosurgery | Cerebrospinal fluid | Discharge | + | - | ST11 | KPC-2 | - | + | - | - |
| P25 | M | 45 | 10 | ICU | Blood | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P26 | F | 38 | 5 | Orthopedics | Respiratory secretions | Discharge | + | + | ST11 | - | NDM-1 | - | - | - |
| P27 | M | 95 | 16 | Respiratory | Respiratory secretions | Discharge | + | + | ST784 | - | - | - | - | - |
| P28 | F | 68 | 18 | Hematology | Blood | Discharge | - | - | ST7 | - | - | - | - | - |
| P29 | F | 85 | 7 | ICU | Secretions | Death | + | + | ST524 | - | - | - | - | - |
| P30 | M | 67 | 22 | Neurosurgery | Cerebrospinal fluid | Discharge | + | - | ST307 | KPC-2 | - | - | - | - |
| P31 | M | 76 | 3 | Neurosurgery | Cerebrospinal fluid | Discharge | + | - | ST11 | KPC-2 | - | + | - | - |

*APACHE II: Acute Physiology and Chronic Health Evaluation II, ST: sequence type, ICU: intensive care unit, mCIM: modified carbapenem inactivation method, eCIM: EDTA-modified carbapenem inactivation method, MLST: multilocus sequence typing, ESBLs: extended spectrum β-lactamases; *: data not publish; —: negative.
now considered as an outbreak, hospital infection management department were notified. The AMS workers ensuring that these measures mentioned in the methods were implemented correctly. With all precautions in place, the outbreak began to wane in September 2018 with only few newly infected patients and no additional spread in the most affected wards (Fig. 1 and Table 1). The outbreak essentially stopped in December 2018. Due to the successful control of the outbreak we are now back to epidemiological stage before the outbreak with sporadic CRKP occurrence. From May to June 2019, CRKP with KPC was detected in two newly CRKP-infected patients with indirect epidemiological connection to the outbreak (Figs. 1 and 2).

A total of 31 patients were affected. These patients did not have a history of travel outside of China, but most of them had frequent hospitalizations in Shanxi province. In 17 (54.8%) patients CRKPs were isolated from respiratory secretions. In seven (22.6%) patients CRKPs were isolated from blood cultures, in four (12.9%) from cerebrospinal fluid, in two (6.5%) from the secretions and in one case (3.2%) from Pus (Table 1).

The age range of the patients was from 30 to 95 years, with an average age of 62.4 years, and 71.0% were male. The average score on the Acute Physiology and Chronic Health Evaluation II (APACHE II) index of these patients was 15.4 (Table 1).

The average number of days spent in hospital was 38.0 days. The average number of days for infection development after first detection of CRKP from patients was 21.0 days, and the median was 12.0 days (Fig. 1). A total of 45.2% of CRKP patients received Carbapenem including treatment in the 90 days before the strains isolated. Among all the patients in this study, 11 (33.3%) died during their hospitalization which the CRKP infection contributed to their death (Table 1).

Antimicrobial susceptibility testing and phenotypic assays
Overall the antibiotics showing the highest susceptibility were tigecycline \((n = 31, 100\%)\), colistin \((n = 30, 96.8\%)\), amikacin \((n = 27, 87.1\%)\) and fosfomycin \((n = 21, 67.7\%)\). MIC range (mg/L) for different carbapenems were imipenem 1 - \(\geq 256\), meropenem 4 - \(\geq 256\) and ertapenem 0.5 - \(\geq 256\). Seven isolates had MIC \(\leq 8\) mg/L for at least one carbapenem. PCR and sequence analysis of carbapenemase genes identified \(\text{blaNDM-1}\) in 14 isolates and \(\text{blaKPC-2}\) in 5 isolates. However, it was worth noting that, eight isolates were positive in mCIM combined eCIM while were negative by PCR (Table 1).

Microbiological investigation of the outbreak
Of the 31 CRKP isolates, 20 (64.5%) were found to produce carbapenemases. However, 6/31 \(K.\ pneumoniae\) isolates were found to harbor genes encoding ESBLs (mainly CTX-M-17 and CTX-M-3), whereas only one harbored AmpC genes (DHA-6). Only one strain was found to express 2 types carbapenemases which were KPC-2 and NDM-1 (Table 1).

The analysis of CRKP revealed a structure dominated by two major genetically distinct lineages; mostly MLST-sequence type belonged to ST11 (21/31) and others such as ST147 \((n = 1)\), ST1 \((n = 1)\). Different strains producing different carbapenemases that were found in both major related clusters belonging to different STs (Fig. 3).
Discussion

We report the investigation of the first hospital outbreak of CRKP in the Second Hospital of Shanxi Medical University, which demonstrated extensive clonal dissemination. The epidemiological investigation showed the two index patients had been transferred to regular wards respectively. With frequent transfer of patients between the different wards, the CRKPs were disseminated to ten wards during the outbreak. According to the dendrogram, the isolates were belonging to two closely related clusters with different STs. Horizontal gene transfer via highly transmissible plasmids from CRKP probably occurred.

It is likely that our patients obtained the isolates within wards from an unknown source after admission. The most frequent sources in hospital outbreaks are the patients themselves, the health care staff, or the environment [20], with the former being the most important epidemiologically. Factors such as immunosuppression, ICU admission, antibiotics exposure including carbapenems, invasive devices are making patients at risk of infections by CRKP [21]. The 31 patients involved in the outbreak had complex, extended or repeated, and overlapping inpatient stays, which lead to an increased risk of multidrug resistance strains infection [22, 23]. Mostly of the patients who received Carbapenem-including treatment in the 90 days before the strains isolated. Extended-spectrum antibiotics use could have played a major role in the loss of intestinal microbiota diversity and made CRKP detection possible in subsequent cultures [24–27]. The duration of CRKP colonization is difficult to anticipate and while many patients do experience spontaneous decolonization within 6 months to a year, multiple hospitalizations and CRE disease can extend duration of carriage [28]. Also several studies emphasize the importance of early identification of carriers for infectious control purposes [29, 30]. According to this, the AMS workers asked physicians to submission of active surveillance cultures timely. Invasive devices and ICU admission has been reported that significantly associated with CRKP strains [31–33]. Here we found that 12 of our patients at ICU and 29 of our patients received invasive devices including 5 neurosurgery patients. Thus, our AMS workers have recommended that surveillance culture of feces or rectal swabs or perianal swabs should be performed as soon as possible after hospital admission or risk exposure. Besides our AMS workers have required all patients with cerebrospinal fluid drawn sanitized by using 0.05% chlorhexidine.

The other CRKP sources are the environment, healthcare workers’ and environmental cleaning staffs’ hands, gloves or gowns contaminated by CRKP isolates, especially some high-touch surfaces in the CRKP positive patient zone, and thus increase potential for transmission [34–36]. During the outbreak, transfer of unknown carriers between healthcare workers and environmental contamination probably happened. An indirect epidemiological link for some CRKP-positive cases were likely obtained the strain from environmental source or via undetected intermediate patient. Outbreaks of K. pneumoniae with persisting environmental reservoir and high resistance to cleaning efforts have been previously reported [37]. According to this, the AMS workers isolated infected patients in a single room,
enhanced chlorhexidine disinfection of the rooms at least three times daily [29, 38] and training sessions in handwashing for healthcare workers.

It also turned out that the infection control methods used previously were not effective in controlling the spread. Our infection control strategies have changed from decentralized management to integrated management now. The assignment of dedicated AMS workers guided by local epidemiology, resource availability and the likely clinical impact of the CRKP outbreak. To support surveillance, enhanced training on epidemiological methods, appropriate data collection and management infrastructure have also implemented. Under the comprehensive management of unified leadership, timely communication, multidisciplinary cooperation and effective surveillance, we successfully controlled the outbreak.

We are now back to epidemiological stage with sporadic CRKP occurrence before the outbreak. The control of CRKP spread is still possible in hospital settings and relies on the use of rapid diagnostic techniques and strict implementation of hygiene measures. The assignment of dedicated AMS workers proved to be crucial and a multimodal and multidisciplinary infection control strategy seems to be most effective. A study compared infection control practices among nine neighboring hospitals in New York (NY, USA) and found that hospitals that used active surveillance cultures had most success in reducing the acquisition rate of KPC-positive organisms [39]. Nevertheless, in our study, it is difficult to say which infection control intervention is the most effective. Infection control interventions generally are implemented as bundles, since no one action can be singled out as effective [5].

The China Antimicrobial Resistance Surveillance Report (http://www.carss.cn/), the largest survey of antimicrobial resistance in China, reported that the rate of carbapenem resistance in K. pneumoniae increased from 8.7% in 2016 (including 1412 tertiary-care hospital and 378 Second-level hospital) to 10.1% in 2018 (including 1353 tertiary-care hospital and 349 Second-level hospital). Fortunately, despite the increasing CRKP prevalence recently in our hospital, cross-species transfer of blaNDM-1 and blaKPC-2 from K. pneumoniae to other Enterobacteriaceae species, particularly Escherichia coli, was not detected during the outbreak. CRKP strains harboring KPC are prevalent in China [40], the United States, Israel, Romania, Greece, Italy, and some parts of the Mediterranean region [41]. According to a CRE network to investigate the epidemiology of CRE in China starting from 2014, only CRKP from the Northwest produced a high level of NDM [40]. Our study showed that NDM-1 (15/31) was the main mechanism of carbapenem resistance during the outbreak. Currently, contact with endemic countries, either by tourism or by healthcare, is considered the main risk factor for NDM-1 acquisition [42, 43].

Our patients did not have a history of travel outside of China, but a number had frequent hospitalizations in Shanxi province, raising concerns regarding the possibility of increasing but unrecognized prevalence of NDM-1 and potential decline in value of travel history a marker of colonization risk. Although 11 strains were negative by PCR, they were highly suspected to be other untested carbapenem enzymes. In Asia, the dominant clone is ST11 CRKP, which accounts for up to 60% of CRKP in China [44]. Consequently, in recent years, ST11 has been regarded as the most transmissible clone contributing to the increasing prevalence of CRKP in China [40]. Our study showed that ST11 was the most abundant K. pneumoniae ST type. Most ST11 CRKP isolates carried NDM-1 carbapenemase.

There have been a few effective drugs to treat CRKP infections, such as ceftazidime-avibactam and colistin. The new antimicrobial drug ceftazidime-avibatam can be used to treat CRKP which has no metalloenzyme [45], and therefore the detection of genotype is also necessary. During the outbreak, Clinical pharmacists put forward suggestions on rational drug use according to the result of phenotypic assays. In cases where there is a lack of effective drugs, combinations of two or more antibiotics are often used in the hopes of achieving a synergistic effect. The Result of mCIM combine with eCIM showed NDM was the main mechanism of carbapenem resistance during the outbreak. NDM-1 confers broad spectrum beta-lactam resistance mediated by hydrolysis of all beta-lactam antimicrobials, with the exception of monobactams, such as aztreonam [9]. Therefore, our AMS workers used tigecycline or colistin in combination with aztreonam for patients with NDM strains in controlling the outbreak.

This study have several limitations. The transmission chain can be further elucidated with a detailed epidemiological investigation, an analysis of plasmids and the use of more discriminatory genotyping such as whole-genome sequencing or pulsed-field gel electrophoresis. Unfortunately, it’s impossible for us now due to the limitation of experimental conditions. Another limitation of our study is the lack of active surveillance cultures results that could probably give useful information about the mode of transmission and the colonization burden of the outbreak-strain. Further work is needed to determine the importance of environmental contamination with CRKP and the effect of effective decontamination on hospital infection rates. Finally, the other limitation of our study was retrospective design.

Conclusions
This study describes an outbreak of 31 CRKP strains presumably cross-transmitted among patients hospitalized in our hospital from October 2017 to August 2019. The assignment of dedicated AMS workers proved to be crucial. The multimodal and multidisciplinary infection
control strategies such as strict contact precautions, isolation, individualized therapy, a comprehensive educational campaign at all levels and strong management seems to be most effective for successful control of the outbreak. The emergence of CRKP in our hospital strengthens the importance of continuing active surveillance cultures, including healthcare workers, common environmental areas and jointly used medical devices on these isolates, thus would help limiting spread of CRKP and improving management.

**Acknowledgements**

The authors thank all staffs from affected wards for their assistance.

**Authors’ contributions**

JD and JZ designed and supervised the study. JK, YS and JS carried out data collection, isolation and identification of CRKP isolates. JZ and QL did PCR and MLST. XL and DY did mCIM and eCIM. JZ, QL and XL wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

**Funding**

This study was supported by the Shanxi Province Natural Science Foundation (grant number 2018033D3124).

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pharmacy, school of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China. 2. Department of Pharmacy, Baotou Hospital of Traditional Mongolian and Chinese Medicine, Baotou, Inner Mongolia, People’s Republic of China. 3. Department of Pharmacy, Second Hospital of Shanxi Medical University, No 382, Wuji Road, Xinghuadistrict, Taiyuan, Shanxi, People’s Republic of China.

**Received:** 21 January 2020 **Accepted:** 11 June 2020

**Published online:** 22 June 2020

**References**

1. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother. 2008(9):11–23 – 37.

2. Tzouvelekis LS, Markogiannakis A, Psychogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25(4):682–707.

3. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36.

4. Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873–84.

5. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(6):1511–61.

6. Wei ZQ, Du XX, Yu YS, Shen P, Chen YG, Li LJ. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother. 2007;51(2):763–5.

7. Li J, Sheng ZK, Deng M, Bi S, Hu FS, Mao HF, Ji ZK, Sheng JF, Li LJ. Epidemiology of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and β-lactamase methylase RmtB in a Chinese University Hospital. BMC Infect Dis. 2012;12:237.

8. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046–54.

8. Wu W, Feng Y, Tang Q, Qiao F, McNally A, Zong Z. NDM metallo-beta-lactamases and their bacterial producers in healthcare settings. Clin Microbiol Rev. 2019;32(2):e00115.

10. Hu F, Guo Y, Yang Y, Zheng Y, Wu S, Jiang X, Zhu D, Wang F. Resistance network reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–81.

11. Poirel L, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae and other Enterobacteriaceae: the impact and evolution of a global menace. J Infect. 2017;6:113.

12. Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2001;45(6):1511–61.

13. Shibata N, Doi Y, Yamane K, Yagi T, Kurokawa H, Shibayama K, Kato H, Kai K, Arakawa Y. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol. 2003;41(11):5407–13.

14. Poirel L, Heritier C, Tolun V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2009;53(12):5046–54.

15. Shiroma K, D’Alessio L, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2001;45(6):1511–61.

16. Shiroma K, D’Alessio L, Steward CD, Alberti S, Bush K, Tenover FC. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2001;45(6):1511–61.

17. Giakkoupi P, Tambic-Andrasevic A, Vourli S, Skrlin J, Sestan-Crnek S, Lucet JC, Moro ML, Tacconelli E, Simonsen GS, et al. Infection prevention and control strategies such as strict contact precautions, isolation, individualized therapy, a comprehensive educational campaign at all levels and strong management seems to be most effective for successful control of the outbreak. The emergence of CRKP in our hospital strengthens the importance of continuing active surveillance cultures, including healthcare workers, common environmental areas and jointly used medical devices on these isolates, thus would help limiting spread of CRKP and improving management.

**Acknowledgements**

The authors thank all staffs from affected wards for their assistance.

**Authors’ contributions**

JD and JZ designed and supervised the study. JK, YS and JS carried out data collection, isolation and identification of CRKP isolates. JZ and QL did PCR and MLST. XL and DY did mCIM and eCIM. JZ, QL and XL wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

**Funding**

This study was supported by the Shanxi Province Natural Science Foundation (grant number 2018033D3124).

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1. Department of Pharmacy, school of Pharmacy, Shanxi Medical University, Taiyuan, Shanxi, People’s Republic of China. 2. Department of Pharmacy, Baotou Hospital of Traditional Mongolian and Chinese Medicine, Baotou, Inner Mongolia, People’s Republic of China. 3. Department of Pharmacy, Second Hospital of Shanxi Medical University, No 382, Wuji Road, Xinghuadistrict, Taiyuan, Shanxi, People’s Republic of China.

**Received:** 21 January 2020 **Accepted:** 11 June 2020 **Published online:** 22 June 2020
pneumonia: a multicenter retrospective study in Shanghai. Clin Infect Dis. 2018;67(suppl_2):S146–S152.
24. Gasink LB, Edlestein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol. 2009;30(12):1180–5.

25. Shtritt P, Reifseld S, Paitan Y, Gottesman BS, Katir M, Paul M, Chowers M. Extended-spectrum beta-lactamase-producing Enterobacteriaceae carriage upon hospital admission: prevalence and risk factors. J Hosp Infect. 2013;83(3):230–2.

26. Luvsanharav UO, Hilar I, Niki M, Nakata A, Yoshinaga A, Yamamoto A, Yamamoto M, Toyoshirina H, Kawakami F, Matsuzara N, et al. Fecal carriage of CTX-M beta-lactamase-producing Enterobacteriaceae in nursing homes in the Kinki region of Japan. Infect Drug Resist. 2013;6:67–70.

27. Pan H, Lou Y, Zeng L, Wang L, Zhang J, Yu W, Qiu Y. Infections caused by carbapenemase-producing Klebsiella pneumoniae: microbiological characteristics and risk factors. Microb Drug Resist. 2019;25(2):287–96.

28. Zimmerman FS, Assous MV, Bolodah-Abram T, Lachish T, Yinnon AM, Wiener-Well Y. Duration of carriage of carbapenem-resistant Enterobacteriaceae following hospital discharge. Am J Infect Control. 2013;41(3):190–4.

29. Ciobotaro P, Oxed M, Nadir E, Bardenstein R, Zimhony O. An effective intervention to limit the spread of an epidemic carbapenem-resistant Klebsiella pneumoniae strain in an acute care setting: from theory to practice. Am J Infect Control. 2011;39(8):671–7.

30. Borer A, Eska T, Nativ R, Saïd-Odès L, Riesenberg K, Livshiz-Riven I, Schlaeffer F, Shef M, Peled N. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in southern Israel. Infect Control Hosp Epidemiol. 2011;32(12):1158–65.

31. Snyder BM, Montague BT, Anandan S, Madabhushi AG, Pragasam AK, Verghese VP, Balaji V, Simoes EAF. Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae. Epidemiol Infect. 2019;147:e137.

32. Corea L, Martinio MD, Siqueira I, Pasternak J, Gales AC, Silva CV, Camargo TZ, Scherer PF, Marra AR. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis. 2013;13:80.

33. Zhang Y, Guo LY, Song WQ, Wang Y, Dong F, Liu G. Risk factors for carbapenem-resistant K. pneumoniae bloodstream infection and predictors of mortality in Chinese paediatric patients. BMC Infect Dis. 2018;18(1):248.

34. Mills MC, Lee J. The threat of carbapenem-resistant bacteria in the environment: evidence of widespread contamination of reservoirs at a global scale. Environ Pollut. 2019;255(Prt 1):113143.

35. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. Curr Opin Infect Dis. 2013;26(4):338–44.

36. Yan Z, Zhou Y, Du M, Bai Y, Liu B, Gong M, Song H, Tong Y, Liu X, Bai Y. Prospective investigation of carbapenem-resistant Klebsiella pneumonia transmission among the staff, environment and patients in five major intensive care units, Beijing, J Hosp Infect. 2019;101(2):150–7.

37. van Beek J, Raisanen K, Broas M, Kauhanen J, Kahkola A, Laine J, Mustonen E, Nukkala T, Pultto P, Sinkkonen J, et al. Tracing local and regional clusters of carbapenemase-producing Klebsiella pneumonia ST512 with whole-genome sequencing, Finland, 2013 to 2018. Euro Surveill. 2019;24(38):1800522.

38. Viale P, Turnietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, Cristini F, Gibertoni C, Venturi S, Cavalli M, et al. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect. 2015;21(6):242–7.

39. Landman D, Babu E, Shah N, Kelly P, Olavole O, Backer M, Bratu S, Quale J. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother. 2012;67(6):1427–31.

40. Wang Q, Wang X, Wang J, Ouyang P, Jin C, Wang R, Zhang Y, Jin L, Chen H, Wang Z, et al. Phenotypic and genotypic characterization of carbapenem-resistant Enterobacteriaceae: data from a longitudinal large-scale CRE study in China (2012–2016). Clin Infect Dis. 2018;67(suppl_2):S196–S205.

41. Navon-Venezia S, Kondratyeva K, Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance. FEMS Microbiol Rev. 2017;41(3):252–75.

42. Kumarasamy KS, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Douni M, Giske CG, Ifan S, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis. 2010;10(9):597–602.

43. Kludkowska M, Pielok LA, Wronska M, Tomczak H. Carbapenemase-producing Enterobacteriaceae in a group of polish travelers returning from south and South-East Asia, June 2017 – June 2018. Environment- or healthcare-associated? Ann Agric Environ Med. 2019;26(3):405–8.

44. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, Li Y, Liao K, Chen S. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. ElBioMedicine. 2017;19:98–106.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomедcentral.com/submissions